Full Length Research Paper
Abstract
Tuberculosis (TB) remains a substantial public health problem due to co-infections, drug resistance, and the genetic diversity of Mycobacterium tuberculosis complex (MTBC). This study sought to evaluate drug resistance and genetic diversity of MTBC isolates from pulmonary TB patients co-infected with HIV and helminths at Jamot Hospital in Yaoundé, Cameroon. A cross-sectional design included 263 smear-positive pulmonary TB patients from April 2022 to March 2023, collecting sputum, blood, and stool samples. Sputum underwent TB culture, drug susceptibility tests, and spoligotyping. HIV was diagnosed with blood-based immunochromatographic tests and confirmed by immunoassay. Helminths in stool were identified using Kato-Katz and Mini-FLOTAC techniques. Among the 263 TB patients, 186 (70.7%) were male, 31 (11.8%) had HIV, and 35 (13.3%) had helminth infections. The drug resistance rate was 20% (26/130), with 6.9% (9/130) classified as multidrug-resistant (MDR), particularly among TB-HIV co-infected patients (66.7%). The predominant families were Cameroon SIT 61 (30.8%, 40/130) and Ghana SIT 53 (15.4%, 20/130). MDR Cameroon SIT 61 was found in TB mono-infected (2/2), helminth (1/1) and HIV (2/6) co-infected patients. This study highlights the impact of co-infections, and the Cameroon SIT 61 family on drug resistance in TB patients, indicating the need for targeted TB management in Cameroon.
Key words: Tuberculosis, co-infections (HIV and helminths), drug resistance, genetic diversity, Cameroon.
Copyright © 2025 Author(s) retain the copyright of this article.
This article is published under the terms of the Creative Commons Attribution License 4.0